Pharmaceuticals

Reviva Pharmaceuticals

Reviva Pharmaceuticals Accepts FDA Recommendation for Second Phase 3 Clinical Trial of Brilaroxazine

Reviva Pharmaceuticals Maintains Buy Rating, Target Price at $2.00

Reviva Pharmaceuticals released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0551 (forecast USD -0.0971)

Reviva Pharmaceuticals released FY2025 9 Months Earnings on November 13, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.3136

Reviva to present Briumvi data on negative symptoms in schizophrenia at CNS Summit

Reviva Pharmaceuticals Holdings Inc. to Hold 2025 Annual Shareholders Meeting

Reviva Pharmaceuticals released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1214 (forecast USD -0.12)

Reviva Pharmaceuticals released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -0.2535

Reviva Pharmaceuticals Holdings, Inc. Plans Initial Public Offering of Common Stock

D. Boral Capital Downgrades Reviva Pharmaceuticals Target Price

Reviva Pharmaceuticals released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1322 (forecast USD -0.21)

Reviva Pharmaceuticals Holdings Inc reports Q1 2025 EPS loss of 13 cents

Reviva Pharmaceuticals released FY2024 annual earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.9025 USD (forecast -0.9733 USD)

Reviva Pharmaceuticals released FY2024 Q4 earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.1633 USD (forecast -0.215 USD)

Reviva Pharmaceuticals Holdings Submits Delayed 10-K SEC Filing, Expects to Report Significant Deficiencies

Reviva Pharmaceuticals Reports 2024 Financial Results, Plans Phase 3 Clinical Trial for Brilaroxazine in 2025

Reviva Pharmaceuticals released FY2024 9 Months Earnings on November 14 (EST) with actual revenue of 0 USD and EPS of -0.7534 USD

Reviva Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2474 USD (forecast -0.246 USD)

HC Wainwright & Co. Analyst Reaffirms Buy Rating for Reviva Pharmaceuticals

Benchmark Analyst Reaffirms Buy Rating on Reviva Pharmaceuticals with $17 Price Target

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap